Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:13:52 ON 10 MAY 2005

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:13:58 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5
DICTIONARY FILE UPDATES: 9 MAY 2005 HIGHEST RN 850130-09-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10664724.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 25 26 27
ring nodes :
1 2 3 4 5 6
chain bonds :
1-26 2-25 3-23 4-22 5-7 6-27 7-8 7-16 7-17 8-9 8-10 9-12 9-19 10-11
10-15 12-13 12-14 14-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-26 2-25 3-23 4-22 6-27 7-16 7-17 8-9 9-12 9-19 12-13 12-14 14-18
exact bonds :
5-7 7-8 8-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15
isolated ring systems :
containing 1 :

G1:H,O,X,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 22:CLASS 23:CLASS 25:CLASS 26:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 14:14:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1335 TO ITERATE

74.9% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 24509 TO 28891
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:14:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 25961 TO ITERATE

100.0% PROCESSED 25961 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L3 13 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 14:14:29 ON 10 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 May 2005 VOL 142 ISS 20
FILE LAST UPDATED: 9 May 2005 (20050509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 10 L3

=> d l4 ibib hitstr abs 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:140787 CAPLUS
DOCUMENT NUMBER: 142:240718
TITLE: Preparation of peptides for treating tumors
INVENTOR(S): Zask, Arie; Kaplan, Joshua; Yamashita, Ayako; Niu, Chuan S.; Birnberg, Gary Harold; Norton, Emily; Cheung, Kinwang; Suayan, Ronald; Sandanayaka, Vincent; Hamann, Philip Ross; Ayral-Kaloustian, Semiramis
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 64 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005037977	A1	20050217	US 2004-911300	20040804
WO 2005016958	A2	20050224	WO 2004-US25246	20040805

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-493841P P 20030808
OTHER SOURCE(S): MARPAT 142:240718
IT **228266-38-4**
RL:. RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides for treating tumors)
RN 228266-38-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB The invention provides peptides A-CH(E)C(:B')NR6CHR7CONR8R9 [A is (un)substituted alkyl, alkenyl, aryl or cyclic hydrocarbyl or aza/oxa/thia analogs; B' is O or H2; E is (un)substituted alkyl, aryl, cyclic hydrocarbyl, etc.; R6-R8 are H or groups defined by A; R9 is an alkyl group which is substituted by sulfonyl, phosphoryl, acyl, hydroxyalkyl, etc.] which exhibit anticancer activity. Thus, N,β,β,3-tetramethyl-L-phenylalanyl-N1-[(1S,2E)-1-isopropyl-3-methyl-4-morpholino-4-oxobut-2-enyl]-N1,3-dimethyl-L-valinamide was prepared and showed IC50 values 19.5, 56 and 1514 nM against KB, KB85 and KBV1 cell lines and 79% inhibition of tubulin polymerization at 0.3 μN.

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:999664 CAPLUS
DOCUMENT NUMBER: 141:395816
TITLE: Preparation of hemiasterlin derivatives as antitumor agents
INVENTOR(S): Kowalczyk, James J.; Kuznetsov, Galina; Schiller,

Shawn; Seletsky, Boris M.; Spyvee, Mark; Yang, Hu
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 237 pp., Cont.-in-part of Appl. No. PCT/US03/08888.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229819	A1	20041118	US 2003-667864	20030922
WO 2003082268	A2	20031009	WO 2003-US8888	20030321
WO 2003082268	A3	20040923		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2005030794	A2	20050407	WO 2004-US30921	20040922

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2002-366592P	P	20020322
	WO 2003-US8888	A2	20030321
	US 2003-667864	A	20030922

OTHER SOURCE(S): MARPAT 141:395816

IT **228266-38-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hemiasterlin derivs. as antitumor agents)

RN 228266-38-4 CAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



I

AB The invention provides compds. R1R2N(CR3R4)n-X1-NR5CHR6CONR7-R-X2-Q [R is an aliphatic, alicyclic, heteroaliph., heteroalicyclic, aryl or heteroaryl moiety; n is 0-4; X1, X2 are CRARB, CO, or SO2, where RA, RB are H or R; R1, R2 are H, OH, CORC or R, where RC is H, OH, CORD, or R and RD is R; R3, R4 are H or R; R5, R6, R7 are H, CORE or R, where RE is H, OH, ORF, or R and RF is a group defined by R; R7 may be absent when NR7 is linked to R via a double bond; two R1-R4 or two R5-R7 taken together may form a (hetero)alicyclic, (hetero)alicyclic(aryl), (hetero)alicyclic(heteroaryl), or (hetero)aryl moiety; Q is ORQ', SRQ', NRQ'RQ'', N3, NOH, or R, where RQ' and RQ'' are H or R or may combine as for R1-R4 or R5-R7 (with provisos)] or their pharmaceutically-acceptable derivs. for use in the treatment of cancer. Compds. of the invention, e.g., hemiasterlin derivative I, were prepared and assayed for inhibition of cell growth. Active compds. were evaluated in the reversibility, MDR, mouse serum stability, and other assays.

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2004:791943 CAPLUS
DOCUMENT NUMBER:	142:6801
TITLE:	Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment
AUTHOR(S):	Yamashita, Ayako; Norton, Emily B.; Kaplan, Joshua A.; Niu, Chuan; Loganzo, Frank; Hernandez, Richard; Beyer, Carl F.; Annable, Tami; Musto, Sylvia; Discafani, Carolyn; Zask, Arie; Ayral-Kaloustian, Semiramis
CORPORATE SOURCE:	Chemical and Screening Sciences and Oncology Research, Wyeth Research, Pearl River, NY, 10965, USA
SOURCE:	Bioorganic & Medicinal Chemistry Letters (2004), 14(21), 5317-5322 CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER:	Elsevier B.V.
DOCUMENT TYPE:	Journal
LANGUAGE:	English

IT **676627-37-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and activity of A segment modified analogs of hemiasterlin as inhibitors of tubulin polymerization)

RN 676627-37-5 CAPLUS

CN Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β,2-tetramethyl- (9CI) (CA INDEX NAME)



GI



I

AB Analogs, such as I, of hemiasterlin and HTI-286, which contain various aromatic rings in the A segment, were synthesized as potential inhibitors of tubulin polymerization The structure-activity relationships related to stereo- and regio-chemical effects of substituents on the aromatic ring in the A segment were studied. Analogs, which carry a meta-substituted Ph ring in the A segment show comparable activity for inhibition of tubulin polymerization to HTI-286, as well as in the cell proliferation assay using KB cells containing P-glycoprotein, compared to those of hemiasterlin and HTI-286.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:617803 CAPLUS

DOCUMENT NUMBER: 141:314607

TITLE: Synthesis and Biological Activity of Analogues of the Antimicrotubule Agent N,β,β-Trimethyl-L-phenylalanyl-N1-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N1,3-dimethyl-L-valinamide (HTI-286)

AUTHOR(S): Zask, Arie; Birnberg, Gary; Cheung, Katherine; Kaplan, Joshua; Niu, Chuan; Norton, Emily; Suayan, Ronald; Yamashita, Ayako; Cole, Derek; Tang, Zhilian; Krishnamurthy, Girija; Williamson, Robert; Khafizova, Gulnaz; Musto, Sylvia; Hernandez, Richard; Annable, Tami; Yang, Xiaoran; Discafani, Carolyn; Beyer, Carl; Greenberger, Lee M.; Loganzo, Frank; Ayral-Kaloustian, Semiramis

CORPORATE SOURCE: Chemical and Screening Sciences, and Oncology Research, Wyeth Research, Pearl River, NY, 10965, USA
SOURCE: Journal of Medicinal Chemistry (2004), 47(19), 4774-4786
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:314607

IT **228266-38-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of analogs of peptide HTI-286 and SAR study of their anticancer activity and effects on microtubule polymerization)

RN 228266-38-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



I

AB Hemiasterlin, a tripeptide isolated from marine sponges, induces microtubule depolymn. and mitotic arrest in cells. HTI-286, an analog from an initial study of the hemiasterlins, is presently in clin. trials. In addition to its potent antitumor effects, HTI-286 has the advantage of circumventing the P-glycoprotein-mediated resistance that hampers the efficacy of other antimicrotubule agents such as paclitaxel and vincristine in animal models. This paper describes an in-depth study of the structure-activity relationships (SAR) of analogs of HTI-286, their effects on microtubule polymerization, and their in vitro and in vivo anticancer activity. Regions of the mol. necessary for potent activity are identified. Groups tolerant of modification, leading to novel analogs, are reported. Potent analogs identified through in vivo studies in tumor xenograft models include one superior analog, HTI-042 (I).

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:267285 CAPLUS
DOCUMENT NUMBER: 140:304078
TITLE: Preparation of chiral phenylalanine derivatives from phenylacetonitriles.
INVENTOR(S): Wu, Yanzhong; Megati, Sreenivasulu; Gletsos, Constantine; Kendall, John Thomas; Wilk, Bogdan Kazimierz; Padmanathan, Thurairajah; Raveendranath, Panolil
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026814	A2	20040401	WO 2003-US28661	20030912
WO 2004026814	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004063904	A1	20040401	US 2003-664724	20030918
PRIORITY APPLN. INFO.:			US 2002-412024P P	20020920

OTHER SOURCE(S): CASREACT 140:304078; MARPAT 140:304078
IT **228266-38-4P**
RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral phenylalanine derivs. from phenylacetonitriles)
RN 228266-38-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **676487-35-7P 676487-36-8P 676487-37-9P**

676487-39-1P 676487-40-4P 676487-41-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral phenylalanine derivs. from phenylacetonitriles)

RN 676487-35-7 CAPLUS
CN Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)



RN 676487-36-8 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-, compd. with (αS)-α-methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 228266-38-4
CMF C17 H25 N O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 2627-86-3
CMF C8 H11 N

Absolute stereochemistry. Rotation (-).



RN 676487-37-9 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-, compd. with (αR)-α-[(1S)-1-aminoethyl]benzenemethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 228266-38-4
CMF C17 H25 N O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 492-41-1
CMF C9 H13 N O

Absolute stereochemistry. Rotation (-).



RN 676487-39-1 CAPLUS
CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-, compd. with (αS)-α-[(1R)-1-aminoethyl]benzenemethanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676487-38-0
CMF C17 H25 N O4

Absolute stereochemistry.



CM 2

CRN 37577-28-9
CMF C9 H13 N O

Absolute stereochemistry. Rotation (+).



RN 676487-40-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-, compd. with (αS)-α-methyl-4-nitrobenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 228266-38-4
CMF C17 H25 N O4

Absolute stereochemistry. Rotation (-).



CM 2

CRN 4187-53-5
CMF C8 H10 N2 O2

Absolute stereochemistry. Rotation (-).



RN 676487-41-5 CAPLUS
CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl-, compd. with (αR)-α-methylbenzenemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 676487-38-0
CMF C17 H25 N O4

Absolute stereochemistry.



CM 2

CRN 3886-69-9
CMF C8 H11 N

Absolute stereochemistry. Rotation (+).



GI



I

AB Title compds. (I; R1, R2 = H, halo, alkyl, alkoxy; R3-R5 = alkyl), were prepared by reaction of R1R2C6H3C(R3)2CN with a reducing agent to give R1R2C6H3C(R3)2CHO, reaction of the latter with an alkali metal cyanide and R5NH2 to give R1R2C6H3C(R3)2CH(NHR5)CN, hydrolysis of this with an alkali metal hydroxide to give R1R2C6H3C(R3)2CH(NHR5)CONH2, treatment of the latter with O(CO2R4)2 in the presence of dimethylaminopyridine to give R1R2C6H3C(R3)2CH(NR5CO2R4)CON(CO2R4)2, hydrolysis of this to give R1R2C6H3C(R3)2CH(NR5CO2R4)CO2H, resolution of this with an amine resolving base, and treatment of the salt with alkali metal hydroxide and acidification. The product N-(tert-butoxycarbonyl)-N,β,β-trimethyl-L-phenylalanine is an intermediate for tubulin inhibitors.

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:267231 CAPLUS
DOCUMENT NUMBER: 140:304081
TITLE: Preparation of peptides for treating resistant tumors
INVENTOR(S): Greenberger, Lee Martin; Loganzo, Frank, Jr.; Discafani-Marro, Carolyn Mary; Zask, Arie; Ayral-Kaloustian, Semiramis
PATENT ASSIGNEE(S): Wyeth Holdings Corporation, USA
SOURCE: PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026293	A2	20040401	WO 2003-US29832	20030918
WO 2004026293	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004121965	A1	20040624	US 2003-666722	20030918

PRIORITY APPLN. INFO.: US 2002-411883P P 20020920
OTHER SOURCE(S): MARPAT 140:304081

IT **228266-38-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of peptides for treating resistant tumors)
RN 228266-38-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **676627-37-5P 676627-79-5P 676628-03-8P 676628-12-9P 676630-57-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptides for treating resistant tumors)
RN 676627-37-5 CAPLUS
CN Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β,2-tetramethyl- (9CI) (CA INDEX NAME)



RN 676627-79-5 CAPLUS
CN Phenylalanine, N,4-bis[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)



RN 676628-03-8 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-2-methoxy-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676628-12-9 CAPLUS
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-2-methoxy-N,O,β,β-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676630-57-2 CAPLUS
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-N,O,β,β-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AB The invention provides peptides R1R2NCH(CR3R4R5)CONR6CHR7CONR8R9 [R1-R8 are H or an (un)saturated moiety having a linear, branched, or cyclic skeleton containing 1-10 (un)substituted carbon atoms and 0-4 each nitrogen, oxygen, or sulfur atoms; or R1R2N or R3R4C is a 3- to 7-membered ring; R9 is -Y-CO-Z, where Y is alkyl and Z is OH, SH, NH2, an amino acid residue, etc. (with provisos)] for treating or inhibiting the growth or eradication of tumors which are resistant to at least one chemotherapeutic agent. Thus, N,β,β-trimethyl-L-phenylalanyl-N1-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N1,3-dimethyl-L-valinamide was prepared and shown to be a potent inhibitor of cell growth in 34 tumor cell lines (mean IC50 = 2.1 ± 1.7 nM, median 1.7 nM, range 0.2-7.3 nM) and is distinct from paclitaxel which has an usually large range of activity. The activity is independent of tumor origin and in many cases this peptide is considerably more potent than paclitaxel.

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:796473 CAPLUS
DOCUMENT NUMBER: 139:308008
TITLE: Preparation of hemiasterlin derivatives as antitumor agents
INVENTOR(S): Kowalczyk, James J.; Kuznetsov, Galina; Schiller, Shawn; Seletsky, Boris M.; Spyvee, Mark; Yang, Hu
PATENT ASSIGNEE(S): Eisai Co. Ltd., Japan
SOURCE: PCT Int. Appl., 289 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082268	A2	20031009	WO 2003-US8888	20030321
WO 2003082268	A3	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479764	AA	20031009	CA 2003-2479764	20030321
EP 1490054	A2	20041229	EP 2003-726101	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004229819	A1	20041118	US 2003-667864	20030922
PRIORITY APPLN. INFO.:			US 2002-366592P P	20020322
			WO 2003-US8888 W	20030321

OTHER SOURCE(S): MARPAT 139:308008

IT **228266-38-4**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hemiasterlin derivs. as antitumor agents)

RN 228266-38-4 CAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



I

AB The invention provides compds. R1R2N(CR3R4)n-X1-NR5CHR6CONR7-R-X2-Q [R is an aliphatic, alicyclic, heteroaliph., heteroalicyclic, aryl or heteroaryl moiety; n is 0-4; X1, X2 are CRARB, CO, or SO2, where RA, RB are H or R; R1, R2 are H, OH, CORC or R; RC is H, OH, ORD, or R; RD is R; R3, R4 are H or R; R5, R6, R7 are H, CORE or R; RE is H, OH, ORF, or R; RF is a group

defined by R; R7 may be absent when NR7 is linked to R via a double bond; two R1-R4 or two R5-R7 taken together may form a (hetero)alicyclic, (hetero)alicyclic(aryl), (hetero)alicyclic(heteroaryl), or (hetero)aryl moiety; Q is ORQ', SRQ', NRQ'RQ'', N3, NOH, or R, where RQ' and RQ'' are H or R or may combine as for R1-R4 or R5-R7 (with provisos)] or their pharmaceutically-acceptable derivs. for use in the treatment of cancer. Compds. of the invention, e.g., hemiasterlin derivative I, were prepared and assayed for inhibition of cell growth. Active compds. (IC50 < 20 nM) were evaluated in the reversibility, MDR, and mouse serum stability assays.

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:697040 CAPLUS
DOCUMENT NUMBER: 139:231000
TITLE: Conjugates of ligand, linker and cytotoxic agent, related compositions, and methods for their use
INVENTOR(S): Tarasova, Nadya I.; Michejda, Christopher J.; Dyba, Marcin; Cohran, Carolyn
PATENT ASSIGNEE(S): The Government of the United States of America, Represented by the Secretary Department of Health and Human Services, USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003072754	A2	20030904	WO 2003-US6344	20030227
WO 2003072754	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-360543P P 20020227
US 2002-370189P P 20020405

IT **228266-38-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(conjugates of ligand, linker and cytotoxic agent, related compns., and methods for their use)
RN 228266-38-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



AB The invention discloses conjugates comprising a ligand, a linker, and a cytotoxic agent, in which the linker is a peptide fragment FALA, VLALA, ALAL, ALALA, ChaLALA, ChaChaLAL, NalChaLAL or NalLALA. Compns. containing the conjugates deliver a cytotoxic agent in a cell-specific manner for treating cancer in a mammal. Thus, peptide derivative I (R = VLALAEEEAYGW-Nle-DF-NH2) was prepared by the solid-phase method and showed relatively low cytotoxic activity (IC50 = 1 μM when tested on gastrin receptor-expressing 3T3 cells).

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:58 CAPLUS
DOCUMENT NUMBER: 138:205332
TITLE: Synthesis and Antimitotic/Cytotoxic Activity of Hemiasterlin Analogues
AUTHOR(S): Nieman, James A.; Coleman, John E.; Wallace, Debra J.; Piers, Edward; Lim, Lynette Y.; Roberge, Michel; Andersen, Raymond J.
CORPORATE SOURCE: Department of Chemistry and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T 1Z1, Can.
SOURCE: Journal of Natural Products (2003), 66(2), 183-199
CODEN: JNPRDF; ISSN: 0163-3864
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:205332
IT **228266-38-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antimitotic/cytotoxic activity of peptide hemiasterlin analogs as anticancer agents)
RN 228266-38-4 CAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



I

II

AB The antimitotic sponge tripeptide hemiasterlin (I) and several of its structural analogs have been synthesized and evaluated in cell-based assays for both cytotoxic and antimitotic activity in order to explore the SAR for this promising anticancer drug lead. One synthetic hemiasterlin analog, SPA110, II, showed more potent in vitro cytotoxicity and antimitotic activity than the natural product hemiasterlin, and consequently it has been subjected to thorough preclin. evaluation and targeted for clin. evaluation. The details of the synthesis of hemiasterlin and the analogs and a discussion of how their biol. activities vary with their structures are presented in this paper.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:425787 CAPLUS
DOCUMENT NUMBER: 131:59140
TITLE: Hemiasterlin analogs
INVENTOR(S): Andersen, Raymond; Piers, Edward; Nieman, James; Coleman, John; Roberge, Michel
PATENT ASSIGNEE(S): The University of British Columbia, Can.
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932509	A2	19990701	WO 1998-CA1184	19981218
WO 9932509	A3	19991007		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2225325	AA	19990619	CA 1997-2225325	19971219
CA 2312826	AA	19990701	CA 1998-2312826	19981218
AU 9917459	A1	19990712	AU 1999-17459	19981218
AU 762691	B2	20030703		
EP 1040119	A2	20001004	EP 1998-962157	19981218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9813817	A	20001010	BR 1998-13817	19981218
JP 2001526294	T2	20011218	JP 2000-525446	19981218
NZ 505086	A	20030530	NZ 1998-505086	19981218
PRIORITY APPLN. INFO.:			CA 1997-2225325 A	19971219
			WO 1998-CA1184 W	19981218

OTHER SOURCE(S): MARPAT 131:59140

IT **228266-38-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hemiasterlin analogs)

RN 228266-38-4 CAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-N,β,β-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



GI



I

AB Hemiasterlin analogs R3R4R5CCH(NR1R2)CONR6CHR7CONR8R9 [R1, R2 = H, R, ArR- (R is saturated or unsatd. moiety having a linear, branched, or cyclic skeleton containing 1-10 (un)substituted carbon atoms, 0-4 nitrogen atoms, 0-4 oxygen atoms, 0-4 sulfur atoms; Ar is an aromatic ring) or R1R2N is cyclic amino; R3, R4, R6, R7, R8 = H, R, ArR-; R5 = H, R, ArR-, Ar; R9 = ZCOY- (Y is optionally substituted alkyl; Z = OH, OR, SH, SR, NH2, NHR, NR2, etc.)] were prepared as cytotoxic and anti-mitotic agents. Thus, peptide I trifluoroacetate, prepared via peptide coupling in solution, showed higher antimitotic activity than hemiasterlin.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	49.85	211.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.30	-7.30

STN INTERNATIONAL LOGOFF AT 14:15:03 ON 10 MAY 2005